With mounting competition in Her2-directed breast cancer treatment, Zymeworks’ latecomer struggles to show that it’s better.
The pharma giant resorts to deal-making for a much-needed late-stage IO asset, leaving its own PD-1 agent out in the cold.
Other groups with large disconnects between sellside and investor expectations include Beigene, Alnylam and Acceleron.
The SITC breaks its own embargo, and the ensuing chaos sees Replimune, Iovance and Incyte move.
Investors are piling into biotech IPOs, but the track record of previous years' new issues shows how hard it is to pick winners.
Notable progress with antibody-drug conjugates from Seattle Genetics and Immunomedics drove the biggest Esmo share price moves.
Here's a round up of Vantage's coverage of the 2020 European Society for Medical Oncology congress.